Liquid Dosage

Therapeutical Proteins

Protein-based therapeutics are increasingly being developed as new chemical entities in the pharmaceutical and life science industries. Unlike small molecules, which are typically synthesized using chemical processes, most proteins need to be processed in living systems, mostly by recombinant DNA technology. The proteins can then be produced in their functional form (quaternary structure), rather than by microbial biosynthesis (bacteria/yeast), substantially reducing the downstream stages of the process.

Downloads

GEA Insights

Chilling Danish pastries with purpose

German pastry specialist Wolf ButterBack expands with GEA’s ammonia-based BluX chiller technology that delivers flexible, low-maintenance cooling while helping the company move closer to net zero.

A partnership shaping the soul of pasta

Barilla and GEA unite tradition with innovation at a new R&D pilot plant in Illinois – boosting speed, flexibility & quality while keeping the soul of pasta alive. 🍝

Using everything: How by-product processing reduces food waste

Maximizing the value of every resource is key to a circular economy. Modern technology unlocks the vast potential in animal by-products, transforming side-streams into valuable proteins, fats and biofuels for new, more sustainable value chains.

Receive news from GEA

Stay in touch with GEA innovations and stories by signing up for news from GEA.

Need assistance?

We are here to help! With just a few details we will be able to respond to your inquiry.